Indications for: ARNUITY ELLIPTA
Maintenance treatment of asthma as prophylactic therapy in patients ≥5yrs.
Limitations of Use:
Not for relief of acute bronchospasm.
Base initial dose on previous asthma therapy and disease severity. Not on inhaled corticosteroid: usually initiate at 100mcg once daily; may increase to 200mcg once daily if inadequate response after 2 weeks. Max 200mcg/day. Rinse mouth after use.
<5yrs: not established. 5–11yrs: 50mcg once daily. Rinse mouth after use.
ARNUITY ELLIPTA Contraindications:
Primary treatment of status asthmaticus or acute asthma episodes. Severe hypersensitivity to milk proteins.
ARNUITY ELLIPTA Warnings/Precautions:
Do not exceed recommended dose. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Immunosuppressed. Tuberculosis. Systemic infections (eg, fungal, bacterial, viral, parasitic). Ocular herpes simplex. If exposed to chickenpox or measles, consider immune globulin or antiviral prophylactic therapies. Monitor for adrenal insufficiency when transferring from systemic steroids. Reevaluate periodically. Monitor for hypercorticism and HPA axis suppression (if occurs, discontinue gradually), growth in children, IOP, glaucoma, or cataracts. Consider eye exams if ocular symptoms develop or in long-term use. Discontinue and treat if paradoxical bronchospasm occurs; use alternative therapy. Assess bone mineral density if risk factors exist (eg, prolonged immobilization, osteoporosis, postmenopausal, tobacco use, advanced age, poor nutrition, others). Moderate or severe hepatic impairment; monitor. Elderly. Labor & delivery. Pregnancy; monitor. Nursing mothers.
ARNUITY ELLIPTA Classification:
ARNUITY ELLIPTA Interactions:
Caution with concomitant strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole).
Nasopharyngitis, upper respiratory tract infection, headache, bronchitis, oral candidiasis; hypersensitivity reactions (discontinue if occurs); children: also pharyngitis, viral infection.
Generic Drug Availability:
Dry pwd inhaler—30 doses